Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer

Elizabeth A. Poplin, Patricia LoRusso, Jacob J. Lokich, John J. Gullo, Philip D. Leming, Joseph J. Schulz, Stephen R. Veach, William McCulloch, L. Baker, Philip Schein

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential. The objective of this randomized study was to determine whether WR-2721 would decrease the hematologic toxicity of mitomycin in patients with colorectal cancer resistant to fluorouracil-based therapy. Ninety-seven patients with refractory colorectal cancer were randomized to receive either mitomycin 20 mg/m2 only or the same dose, of mitomycin after pretreatment with WR-2721, 910 mg/m2. The principal toxicity in both groups was thrombocytopenia. The platelet nadirs were lower in patients receiving single-agent mitomycin (P=0.026). Surprisingly, no clinical complete or partial responses were noted in either group, and survival was not different between the two groups. Thus, while WR-2721 decreased the thrombocytopenia associated with mitomycin therapy, mitomycin was ineffective in the treatment of refractory colorectal carcinoma.

Original languageEnglish (US)
Pages (from-to)415-419
Number of pages5
JournalCancer chemotherapy and pharmacology
Volume33
Issue number5
DOIs
StatePublished - Sep 1994
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this